Investigational 2.0 mg dose of ozempic® (semaglutide) demonstrates superior reductions in blood sugar vs ozempic® 1.0 mg in adults with type 2 diabetes in a phase 3 trial

Bagsv Æ rd , denmark, 26 june 2021 – novo nordisk today presented data showing that an investigational 2.0 mg dose of ozempic® (semaglutide) provided statistically significant and superior reductions in blood sugar (hba1c) compared with ozempic® 1.0 mg1. these data were the outcome of the sustain forte trial, a phase 3b, 40-week, efficacy and safety trial comparing once-weekly semaglutide 2.0 mg vs ozempic® 1.0 mg as add-on to metformin with or without sulfonylureas in 961 adults with type 2 diabetes in need of additional blood sugar reduction. the results were presented at the 81st annual scientific sessions of the american diabetes association (ada)1, 2 and primary results are in press for publication in the lancet diabetes & endocrinology.
NVO Ratings Summary
NVO Quant Ranking